KRAS and cancer: Furthermore, PROTAC 80 inhibited the proliferation of a panel of KRAS G12D mutant cancer cell lines, showed good bioavailability in mice, and suppressed the growth in a KRAS G12D-positive AsPC-1 xenograft model.